LY2857785

Binding assays

CDK7 and CDK9 reaction mixtures contained 10 mmol/L Tris-HCl (pH 7.4), 10 mmol/L HEPES, 5 mmol/L DTT, 10 μmol/L ATP, 0.5 μCi 33p-ATP, 10 mmol/L MnCl2, 150 mmol/L NaCl, 0.01% Triton X-100, 2% dimethylsulfoxide (DMSO), 0.05 mmol/L CDK7/9ptide, and 2 nmol/L CDK7/Mat1/cyclin H (14-476M, Upstate), or 2 nmol/L CDK9/cyclin T1 (14-685M, Upstate), respectively. CDK8/cyclin C reaction is performed in HEPES 30 mmol/L, DTT 2 mmol/L, MgCl2 5 mmol/L, 0.015% Triton X-100, 5 μmol/L ATP, and 400 nmol/L of RBER-CHKStide containing 20 nmol/L of enzyme.Compound in DMSO was diluted serially 1:3 for dose response. Reactions were carried out in 96-well polystyrene plates. The reactions were incubated at room temperature for 60 minutes and followed by termination with 10% H3PO4 or 10% trichloroacetic acid (TCA). For the filter binding assay, reactions were transferred to 96-well filter plates and measured by Microbeta scintillation counter.

Cell lines

Human bone marrow myeloid progenitor cells

Preparation method

This compound is soluble in DMSO. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

Cells were treated with varying concentrations of compound for varying durations ranging from 4 to 24 hours.

Applications

LY2857785 inhibited hematologic tumor cell (human bone marrow myeloid progenitor cells) proliferation.

Animal models

Human cancer cells U87MG, MV-4-11, A375, and HCT116 xenograft rat models

Dosage form

4, 8, 18 mg/kg. i.v. every 3 days.

Application

LY2857785 demonstrates potent antitumor growth efficacy in preclinical tumor models (U87MG, MV-4-11, A375, and HCT116 xenograft rat models).

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1] Yin T, et al. A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models. Mol Cancer Ther. 2014 Jun;13(6):1442-56.